News >

Expert Emphasizes Importance of Acalabrutinib Approval in MCL

Angelica Welch
Published: Thursday, Dec 14, 2017

Dr. Michael Wang

Michael Wang, MD,
The treatment of patients with mantle cell lymphoma (MCL) has undergone immense progress in the past year, says Michael Wang, MD. One of the biggest developments was the recent FDA approval of acalabrutinib (Calquence) for patients with relapsed disease.

In an interview with OncLive during the ASH 2017 Annual Meeting, Wang, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discussed the impact of acalabrutinib on patients with MCL, ongoing progress in the field, and The University of Texas MD Anderson Cancer Center’s Lymphoma Moonshot Program.

OncLive: Could you discuss the Lymphoma Moonshot Program?

Wang: B-cell lymphoma is a very common disease affecting many Americans. In the United States, about 0.7 million people live with lymphoma, and B-cell lymphoma accounts for the majority of lymphoma, and it has many subtypes. I am the co-leader of the Lymphoma Moonshot Program at The University of Texas MD Anderson Cancer Center, and the mission of this program is to double the cure rate of B-cell lymphoma from 30% to 60% within 5 to 10 years. We are already 3 years into this program and we are making tremendous progress. The subtypes of B-cell lymphoma include large cell lymphoma, follicular lymphoma, marginal zone lymphoma, and MCL. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication